论文部分内容阅读
目的探讨瑞舒伐他汀对扩张型心肌病伴充血性心力衰竭(CHF)病人心功能和超敏C反应蛋白(hs-CRP)的影响。方法采用随机平行对照的试验方法,选择60例CHF病人,分为观察组和对照组,每组各30例。两组均同时给予指南建议常规治疗,观察组加用瑞舒伐他汀10 mg/d,治疗12周。治疗前后评定心功能分级,检测左室射血分数(LVEF)、左室舒张末内径(LVEDD)、血总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、hs-CRP水平。结果观察组治疗后LVEF显著增加,LVEDD显著缩小,TC、TG、LDL-C、hs-CRP显著降低,差异有统计学意义(P<0.05或P<0.01);对照组治疗后LVEF显著增加,LVEDD显著缩小,hs-CRP显著降低,差异有统计学意义(P<0.05)。两组治疗后比较,LVEF、LVEDD、TC、TG、LDL-C、hs-CRP均有统计学意义(P<0.05)。结论瑞舒伐他汀可以进一步改善CHF病人的心功能,同时显著降低TC、TG、LDL-C、hs-CRP水平。
Objective To investigate the effect of rosuvastatin on cardiac function and hs-CRP in patients with dilated cardiomyopathy and congestive heart failure (CHF). Methods Randomized controlled trial was used to select 60 patients with CHF, divided into observation group and control group, 30 cases in each group. Both groups were given guidelines recommended routine treatment, the observation group with rosuvastatin 10 mg / d, for 12 weeks. Cardiac function was assessed before and after treatment. Left ventricular ejection fraction (LVEF), left ventricular end diastolic dimension (LVEDD), total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL- , High-density lipoprotein cholesterol (HDL-C), hs-CRP levels. Results After treatment, LVEF was significantly increased, LVEDD was significantly reduced, TC, TG, LDL-C and hs-CRP were significantly decreased in the observation group (P <0.05 or P <0.01) LVEDD was significantly reduced, hs-CRP was significantly reduced, the difference was statistically significant (P <0.05). After treatment, LVEF, LVEDD, TC, TG, LDL-C, hs-CRP were statistically significant (P <0.05). Conclusion Rosuvastatin can further improve the cardiac function of patients with CHF, and significantly reduce the levels of TC, TG, LDL-C and hs-CRP.